Success Metrics

Clinical Success Rate
95.0%

Based on 19 completed trials

Completion Rate
95%(19/20)
Active Trials
0(0%)
Results Posted
26%(5 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_1
1
4%
Ph not_applicable
2
8%
Ph early_phase_1
1
4%
Ph phase_2
7
28%
Ph phase_4
11
44%
Ph phase_3
2
8%

Phase Distribution

2

Early Stage

7

Mid Stage

13

Late Stage

Phase Distribution24 total trials
Early Phase 1First-in-human
1(4.2%)
Phase 1Safety & dosage
1(4.2%)
Phase 2Efficacy & side effects
7(29.2%)
Phase 3Large-scale testing
2(8.3%)
Phase 4Post-market surveillance
11(45.8%)
N/ANon-phased studies
2(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.0%

19 of 20 finished

Non-Completion Rate

5.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

25

all time

Status Distribution
Completed(19)
Terminated(1)
Other(5)

Detailed Status

Completed19
unknown5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
0
Success Rate
95.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.2%)
Phase 11 (4.2%)
Phase 27 (29.2%)
Phase 32 (8.3%)
Phase 411 (45.8%)
N/A2 (8.3%)

Trials by Status

unknown520%
completed1976%
terminated14%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT04645550Phase 4

Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT)

Completed
NCT03015974

Registry of IgA Nephropathy in Chinese Children

Unknown
NCT02565693Phase 2

Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation

Completed
NCT00349973Not Applicable

Clinical Trial of Dipyridamole in Schizophrenia

Completed
NCT02121756Phase 1

Dipyridamole for Immune Activation in HIV

Completed
NCT02247414Phase 4

Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection

Completed
NCT02238444Phase 4

Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

Unknown
NCT00763009Phase 4

Persantine: Variation in Response Trial

Terminated
NCT00560079Phase 4

Efficacy of Allopurinol and Dypiridamole in Acute Mania

Completed
NCT02782260Phase 2

Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium

Unknown
NCT00767663Phase 4

Persantin Preceding Elective PCI

Completed
NCT02251184Phase 4

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

Completed
NCT01369745Phase 2

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

Completed
NCT00551707Phase 2

Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis

Completed
NCT00000527Phase 2

Recurrent Carotid Stenosis

Completed
NCT00000496Phase 3

Platelet Drug Trial in Coronary Disease Progression

Completed
NCT00000510Phase 3

Platelet-Inhibitor Drug Trial in Coronary Angioplasty

Completed
NCT00002487Phase 2

Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer

Unknown
NCT01295567Phase 4

Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)?

Completed
NCT00003018Phase 2

S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
25